Pawel Bialk is a Principal Investigator of the Genome Technologies group at the Gene Editing Institute. As PI, Pawel leads a group that focuses on two areas. One area of focus is with the clinical development of CRISPR based therapies, specializing in assessing CRISPR off-target activity. He also leads early studies establishing new targetable sequences as viable therapeutic targets for pipeline development. Pawel’s other area of focus is on leading the development of custom gene engineered cell lines as a fee for service to both academic and industry entities. He received his B.S. from Mercyhurst University and his M.S. in biology from Delaware State University, where he studied the potential of TALENs and CRISPR/Cas9 systems in conjunction with single-stranded DNA repair templates to enhance the efficiency of specific events in the gene editing reaction.
